Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries

Conclusions: In considered countries specific regulations on reimbursement of orphan drugs are valid but in Lithuania and Romania no formal HTA process was employed; in case of some countries higher ICER values for orphans are used. The share of reimbursed orphan drugs varied significantly across the countries, but it was not associated with GDP per capita.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research